We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00171548
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : September 22, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:

Metabolic syndrome is commonly defined as a set of risk factors and abnormalities that markedly increase the risk of cardiovascular events. Its relevance has been confirmed by a recent population-based survey of subjects aged 40-79 years indicating that the prevalence of metabolic syndrome in Italy is 34.1% if diagnosed using WHO criteria and 17.8% if diagnosed using the NCEP-ATPIII criteria.

On the basis of the above considerations, the aim of this study is to promote the use of the SCORE algorithm for estimating cardiovascular risk, and to evaluate its evolution in patients with metabolic syndrome after the implementation of a multifactorial preventive strategy, with particular reference to the correction of lifestyle, hypertension and dyslipidemia.


Condition or disease Phase
Metabolic Syndrome Phase 4

Study Design

Study Type : Observational
Actual Enrollment : 600 participants
Time Perspective: Prospective
Official Title: Project to Promote the Evaluation of Cardiovascular Risk in Clinical Practice, and Assess Its Evolution After the Implementation of Multifactorial Preventive Strategy Aimed at Reducing the Level of Global Risk (SCORE Algorithm) in Subjects With Metabolic Syndrome and a Risk Level of 5%
Study Start Date : October 2004
Primary Completion Date : July 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients of both genders aged 40-65 years.
  • A diagnosis of metabolic syndrome formulated on the basis of the criteria proposed by the NCEP - Adult Panel III: i.e. the presence of at least three of the following conditions:

    1. Waist circumference >102 cm in men and >88 cm in women
    2. Triglyceridemia 150 mg/dl
    3. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women
    4. Sitting arterial pressure 130/85 mmHg
    5. Fasting glycemia 110 mg/dl
  • A risk of cardiovascular death of >5% at the current age of the patient or >5% if projected to an age of 60 years, as calculated by means of the SCORE algorithm using the table based on the total/HDL cholesterol ratio relating to low-risk populations and appropriate for Italy.
  • Written informed consent.

Exclusion Criteria:

  • Women who have not been in menopause for at least one year or are not surgically sterile, and do not use an effective contraceptive method, such as spermicidal barrier methods or intrauterine devices. The use of oral contraceptives is not allowed.
  • Known or suspected hypersensitivity to valsartan and/or fluvastatin, or other contraindications to their use;
  • A positive history of ischemic heart disease, peripheral artery disease or cerebral vasculopathy;
  • Patients with an SBP of 180 mmHg and/or DBP of 110 mmHg.
  • Patients with severe medical conditions which, in the judgement of the Investigator, contraindicate trial participation or significantly limit life expectancy;
  • Treatment with drugs able to modify the lipid profile (ongoing or in the three months preceding trial entry);
  • Patients unable to follow the planned protocol procedures or sign the informed consent form.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00171548


Locations
Switzerland
Novartis Pharmaceuticals
Basel, Switzerland
Sponsors and Collaborators
Novartis
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information

Responsible Party: External Affairs, Novartis
ClinicalTrials.gov Identifier: NCT00171548     History of Changes
Other Study ID Numbers: CVAL489AIT05
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: September 22, 2008
Last Verified: September 2008

Keywords provided by Novartis:
Metabolic syndrome, cardiovascular risk reduction

Additional relevant MeSH terms:
Syndrome
Metabolic Syndrome X
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases